CA2870711A1 - Neuroprotective composition and method of use - Google Patents
Neuroprotective composition and method of use Download PDFInfo
- Publication number
- CA2870711A1 CA2870711A1 CA2870711A CA2870711A CA2870711A1 CA 2870711 A1 CA2870711 A1 CA 2870711A1 CA 2870711 A CA2870711 A CA 2870711A CA 2870711 A CA2870711 A CA 2870711A CA 2870711 A1 CA2870711 A1 CA 2870711A1
- Authority
- CA
- Canada
- Prior art keywords
- polyarginine peptide
- peptide
- cysteines
- polyarginine
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title abstract description 30
- 230000000324 neuroprotective effect Effects 0.000 title description 4
- 108010011110 polyarginine Proteins 0.000 claims abstract description 35
- 235000018417 cysteine Nutrition 0.000 claims abstract description 33
- 235000009697 arginine Nutrition 0.000 claims abstract description 19
- 150000001945 cysteines Chemical group 0.000 claims abstract description 19
- 230000006378 damage Effects 0.000 claims abstract description 15
- 208000014674 injury Diseases 0.000 claims abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 12
- 150000001484 arginines Chemical class 0.000 claims abstract description 10
- 230000001537 neural effect Effects 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
- 230000003466 anti-cipated effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000029028 brain injury Diseases 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 208000006011 Stroke Diseases 0.000 description 22
- 208000030886 Traumatic Brain injury Diseases 0.000 description 19
- 230000009529 traumatic brain injury Effects 0.000 description 18
- 210000001525 retina Anatomy 0.000 description 12
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004112 neuroprotection Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000016273 neuron death Effects 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 231100000318 excitotoxic Toxicity 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 210000001116 retinal neuron Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 229940117892 Glutamate receptor agonist Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001181114 Neta Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010048955 Retinal toxicity Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000005731 poly ADP ribosylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 231100000385 retinal toxicity Toxicity 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013417 toxicology model Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625349P | 2012-04-17 | 2012-04-17 | |
| US61/625,349 | 2012-04-17 | ||
| PCT/US2013/036938 WO2013158739A1 (en) | 2012-04-17 | 2013-04-17 | Neuroprotective composition and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2870711A1 true CA2870711A1 (en) | 2013-10-24 |
Family
ID=49384027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870711A Abandoned CA2870711A1 (en) | 2012-04-17 | 2013-04-17 | Neuroprotective composition and method of use |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150126457A1 (enExample) |
| EP (1) | EP2872160A4 (enExample) |
| JP (1) | JP2015514771A (enExample) |
| AU (1) | AU2013249337A1 (enExample) |
| CA (1) | CA2870711A1 (enExample) |
| WO (1) | WO2013158739A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872160A4 (en) | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
| CN106170491B (zh) * | 2013-10-30 | 2020-07-24 | 阿尔杰妮卡治疗学有限公司 | 神经保护肽 |
| US20170114093A1 (en) * | 2015-05-29 | 2017-04-27 | Andrew Peter Mallon | Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection |
| US20210101935A1 (en) | 2019-10-02 | 2021-04-08 | Brown University | Cyclic peptidomimetic for the treatment of neurological disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| US20130012447A1 (en) * | 2007-08-27 | 2013-01-10 | Eiketsu Sho | Protein kinase c-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| JP5816550B2 (ja) * | 2009-06-22 | 2015-11-18 | 株式会社メディネット | 蛋白質の修飾剤 |
| EP2459208B1 (en) * | 2009-07-29 | 2016-09-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2872160A4 (en) | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
-
2013
- 2013-04-17 EP EP13777758.7A patent/EP2872160A4/en not_active Withdrawn
- 2013-04-17 AU AU2013249337A patent/AU2013249337A1/en not_active Abandoned
- 2013-04-17 JP JP2015507143A patent/JP2015514771A/ja active Pending
- 2013-04-17 WO PCT/US2013/036938 patent/WO2013158739A1/en not_active Ceased
- 2013-04-17 US US14/391,293 patent/US20150126457A1/en not_active Abandoned
- 2013-04-17 CA CA2870711A patent/CA2870711A1/en not_active Abandoned
-
2016
- 2016-12-29 US US15/393,720 patent/US10040822B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2872160A1 (en) | 2015-05-20 |
| EP2872160A4 (en) | 2015-11-25 |
| US20170107253A1 (en) | 2017-04-20 |
| WO2013158739A1 (en) | 2013-10-24 |
| AU2013249337A1 (en) | 2014-10-30 |
| US20150126457A1 (en) | 2015-05-07 |
| US10040822B2 (en) | 2018-08-07 |
| JP2015514771A (ja) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11413308B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| US10040822B2 (en) | Neuroprotective composition and method of use | |
| McManus et al. | Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders | |
| US20210085749A1 (en) | Therapeutic and Neuroprotective Peptides | |
| Dudin et al. | Scorpion sting in children in the Jerusalem area: a review of 54 cases | |
| CA2506481A1 (en) | Method of treatment of conditions by administration of streptolysin o | |
| KR20250004041A (ko) | 삼차 신경통 치료 및 그와 관련된 통증 감소에 사용하기 위한 트리메프라진 | |
| WO2018129231A1 (en) | Method for treating multiple sclerosis | |
| WO2022094565A1 (en) | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders | |
| KR101196176B1 (ko) | 뇌졸중 후의 반사성 교감 신경성 디스트로피 발증 예방제 | |
| US11759451B2 (en) | Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury | |
| Kanthasamy et al. | Antimyoclonic and neuroprotective effects of lamotrigine in an animal model of cardiac arrest | |
| CA3042013C (en) | Pharmaceutical composition and method of treating female sexual dysfunctions | |
| EA051660B1 (ru) | Способ лечения черепно-мозговой травмы и средство для его осуществления | |
| Al-Humaidan et al. | Can propofol cause dystonia and movement disorders? | |
| RU2659674C1 (ru) | Способ лечения цереброваскулярных нарушений головного мозга (варианты) | |
| TWI306770B (en) | Pharmaceutical composition for rescuring learning or memory deficits | |
| EP4719440A1 (en) | Compositions of blood plasma fractions and blood plasma subfractions and their use in treatment of disease | |
| Litvinenko et al. | Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease and Potential for Pathogenetic Therapy | |
| Genis | Neuroprotective Agents for Traumatic Brain Injury: Theoretical Therapy or the Future of Treatment? | |
| Wegmann | Neuroprotective measures in traumatic brain injury patients | |
| KR20260005778A (ko) | 탈수초 질환 치료를 위한 펩타이드 및 IVIg의 병용 요법 | |
| US20240316143A1 (en) | Therapeutic agents and/or pharmaceutical compositions for neurocognitive disorders | |
| US8664209B2 (en) | Daptomycin for multiple sclerosis | |
| NZ758615B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180227 |
|
| FZDE | Discontinued |
Effective date: 20200831 |